Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors - PubMed (original) (raw)
. 1999 Oct;291(1):409-15.
Affiliations
- PMID: 10490931
Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors
N D Volkow et al. J Pharmacol Exp Ther. 1999 Oct.
Abstract
Increases in dopamine concentration in limbic brain regions have been postulated to underlie the reinforcing effects of psychostimulant drugs in laboratory animals. However, neither the qualitative nor the quantitative relationship between drug-induced increases in brain dopamine and the reinforcing effects of psychostimulant drugs have been investigated in humans. Positron emission tomograph and [(11)C]raclopride, a dopamine D(2) receptor radioligand that competes with endogenous dopamine for occupancy of the D(2) receptors, were used to measure changes in brain dopamine after different doses of i.v. methylphenidate in 14 healthy controls. In parallel, measures for self-reports of drug effects were obtained to assess their relationship to methylphenidate-induced changes in brain dopamine. The intensity of the "high" induced by methylphenidate was significantly correlated with the levels of released dopamine (r = 0.78, p <.001); subjects having the greatest increases were those who perceived the most intense high. This relationship remained significant after partialing out for dose and concentration of methylphenidate in plasma. Furthermore, subjects for whom methylphenidate did not increase dopamine did not perceive a high. These results represent the first clear demonstration that stimulant-induced high, a mood descriptor that reflects reinforcing effects of drugs in humans, is associated with increases in brain dopamine, and also that there is a quantitative relationship between levels of D(2) receptor occupancy by dopamine and the intensity of the high.
Similar articles
- Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma.
Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, Zhu W, Swanson JM. Volkow ND, et al. Psychopharmacology (Berl). 2003 Mar;166(3):264-70. doi: 10.1007/s00213-002-1340-7. Epub 2003 Feb 13. Psychopharmacology (Berl). 2003. PMID: 12589522 Clinical Trial. - Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels.
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, Hitzemann R, Ding YS, Pappas N. Volkow ND, et al. Am J Psychiatry. 1999 Sep;156(9):1440-3. doi: 10.1176/ajp.156.9.1440. Am J Psychiatry. 1999. PMID: 10484959 - Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction.
Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, Pappas N. Volkow ND, et al. Am J Psychiatry. 1999 Jan;156(1):19-26. doi: 10.1176/ajp.156.1.19. Am J Psychiatry. 1999. PMID: 9892293 - Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.
Volkow ND, Swanson JM. Volkow ND, et al. Am J Psychiatry. 2003 Nov;160(11):1909-18. doi: 10.1176/appi.ajp.160.11.1909. Am J Psychiatry. 2003. PMID: 14594733 Review. - Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies.
Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ. Volkow ND, et al. Eur Neuropsychopharmacol. 2002 Dec;12(6):557-66. doi: 10.1016/s0924-977x(02)00104-9. Eur Neuropsychopharmacol. 2002. PMID: 12468018 Review.
Cited by
- Brain connectivity changes to fast versus slow dopamine increases.
Manza P, Tomasi D, Vines L, Sotelo D, Yonga MV, Wang GJ, Volkow ND. Manza P, et al. Neuropsychopharmacology. 2024 May;49(6):924-932. doi: 10.1038/s41386-024-01803-8. Epub 2024 Feb 7. Neuropsychopharmacology. 2024. PMID: 38326458 Free PMC article. Clinical Trial. - Lack of effect of methamphetamine on reward-related brain activity in healthy adults.
Haggarty CJ, Glazer JE, Nusslock R, Lee R, de Wit H. Haggarty CJ, et al. Psychopharmacology (Berl). 2024 Jan;241(1):181-193. doi: 10.1007/s00213-023-06475-8. Epub 2023 Dec 23. Psychopharmacology (Berl). 2024. PMID: 38141075 Clinical Trial. - Neural circuit selective for fast but not slow dopamine increases in drug reward.
Manza P, Tomasi D, Shokri-Kojori E, Zhang R, Kroll D, Feldman D, McPherson K, Biesecker C, Dennis E, Johnson A, Yuan K, Wang WT, Yonga MV, Wang GJ, Volkow ND. Manza P, et al. Nat Commun. 2023 Nov 8;14(1):6408. doi: 10.1038/s41467-023-41972-6. Nat Commun. 2023. PMID: 37938560 Free PMC article. - Role of nucleus accumbens dopamine 2 receptors in motivating cocaine use in male and female rats prior to and following the development of an addiction-like phenotype.
Towers EB, Williams IL, Qillawala EI, Lynch WJ. Towers EB, et al. Front Pharmacol. 2023 Jul 26;14:1237990. doi: 10.3389/fphar.2023.1237990. eCollection 2023. Front Pharmacol. 2023. PMID: 37564182 Free PMC article. - The traps of adaptation: Addiction as maladaptive referent-dependent evaluation.
Rigoli F, Pezzulo G. Rigoli F, et al. Cogn Affect Behav Neurosci. 2023 Aug;23(4):973-985. doi: 10.3758/s13415-023-01086-4. Epub 2023 Apr 4. Cogn Affect Behav Neurosci. 2023. PMID: 37016202 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources